SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
Status:
Completed
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in
plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP
following SGLT2 inhibition.
Phase:
Phase 3
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)